The AJMC® Psoriasis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin disease, which tends to go through cycles where it flares and goes into remission.
May 14th 2024
Botulinum toxin A (BoNT-A) exhibited promising results for nail psoriasis for up to 6 months with a single injection.
Therapeutic Advances in Plaque Psoriasis to Address Unmet Needs in Treatment and Improve Patient Outcomes
1.5 Credits / Dermatology
View More
Managed Care Considerations for Management of Molluscum Contagiosum: Examining Emerging Treatments
1.0 Credit / Dermatology
View More
AJMC® Powered by Patients and Managed Care Insights – More Than a Cosmetic Disease: Vitiligo Treatment Approaches and Raising Awareness of the Disease Burden
1.5 Credits / Dermatology
View More
Advancing Patient Outcomes in Hidradenitis Suppurativa: Updates and Strategies for Managed Care
1.5 Credits / Dermatology
View More
Treatment Gaps in the Management of Generalized Pustular Psoriasis: Enhancing the Role of Managed Care
1.5 Credits / Dermatology, Immunology
View More
Early Levels of Ustekinumab May Predict Longer-term Response in Patients With Psoriasis
September 21st 2019Measurement of drug levels early in treatment with ustekinumab for patients with psoriasis may be able to successfully predict patient response and, therefore, direct a treatment strategy.
Read More
Researchers Examine Metabolic Syndrome Links to Inflammatory Skin Disorder Lichen Planus
September 20th 2019Psoriasis is known to be linked with metabolic syndrome, which is triggered by chronic inflammation and fosters obesity and dyslipidemia. A recent study looked at another chronic inflammatory skin disease, lichen planus, to better understand any associations with metabolic syndrome.
Read More
Could Understanding HLA-C Lead to Precision Therapy in Psoriatic Arthritis?
September 9th 2019Human leukocyte antigen c (HLA‐C), a protein encoded by the HLA-C gene, plays an important role in protecting against both cancer and viruses. At the same time, it has been implicated in autoimmune diseases, including rheumatic diseases, though the mechanism by which it contributes to the pathogenesis of these diseases is not yet clear.
Read More
Treating RA With Anti-TNF Agents Is Linked With a Higher Risk of Incident Psoriasis
August 19th 2019Biologics have become the standard of care for rheumatoid arthritis (RA) that fails to respond adequately to conventional disease-modifying antirheumatic agents (DMARDs), and overall, these agents are safe and effective. However, an association between treatment with anti–tumor necrosis factor (anti-TNF) agents and new-onset psoriasis in patients with RA has been observed.
Read More
Obesity, Insulin Resistance Are Linked With Advanced Liver Fibrosis in Patients With Psoriasis
August 12th 2019“Our data suggest that people with central obesity, insulin resistance, and active psoriasis are the most at risk for liver fibrosis,” wrote the authors, and “if use of methotrexate is a risk factor, it is not the only risk factor and for most patients it is unlikely to be the most important risk factor.”
Read More
During a recent meeting of the British Association of Dermatologists, a team of researchers from the United Kingdom reported on a systematic review of literature on adults exposed to biologics during conception and/or pregnancy, and they report that they did not find increased risk to the fetus following maternal or paternal biologic exposure.
Read More
Meta-Analysis Shows Patients With Psoriasis at Significantly Elevated Risk for Cancer
July 29th 2019In a study presented at the British Association of Dermatologists’ 99th Annual Meeting in Liverpool, United Kingdom, July 2-4, 2019, researchers from the University of Manchester and the Salford Royal National Health Service Foundation Trust reported on an effort to assess evidence on the risk of cancer in patients with psoriasis. They found that there are a number of site-specific cancers for which patients with psoriasis are at elevated risk.
Read More
Biologic Treatment Is Associated With Better Bone Health in Patients With Psoriatic Arthritis
July 23rd 2019Given that psoriatic arthritis is associated with increased fracture risk, neutralizing the key proinflammatory and bone-destructive mediators of the disease, wrote the authors, appears to be important to restoring bone health.
Read More
Treating Psoriasis With Biologics May Have Cardiac Benefits
July 15th 2019The use of biologics to treat psoriasis has increased over time, and a recent study has demonstrated that these drugs may have benefits that extend well beyond clearing patients’ skin. The study, published in Cardiovascular Research, found that biologic therapy for psoriasis was associated with a reduction in coronary artery disease.
Read More
Psoriasis Risk Rises Along With BMI, Research Finds
July 9th 2019A recent study used Mendelian randomization, which uses genetic variants to randomly allocate individuals to groups based on genotype, to further investigate the causal relationship between body mass index (BMI) and psoriasis. It found that as BMI rises, so too does the risk for developing psoriasis.
Read More
Examining Treatment Patterns of Patients With Moderate-to-Severe Plaque Psoriasis
July 2nd 2019A recent study examined prescription claims databases to determine treatment patterns of patients with moderate-to-severe psoriasis who started therapy with 1 of 5 drugs by later status of whether they had psoriatic arthritis or not.
Read More
Are TNF Inhibitors Safe in Pregnancy?
November 2nd 2018A review published in the International Journal of Molecular Sciences highlights existing knowledge gaps in understanding the safety and impact of tumor necrosis factor (TNF) α inhibitors in pregnant women suffering from inflammatory conditions such as psoriasis and rhaumatoid arthritis.
Read More
Review Finds Several Biologics Effective in Treating Form of Palmoplantar Psoriasis
December 13th 2017A systematic review of biologics used in to treat palmoplantar psoriasis and palmoplantar pustulosis, 2 diseases that affect the palms and the soles of feet, found several available biologics are at least 80% effective in 1 form of the disease, but that there is less data on how well these drugs work on other forms of the disease.
Read More